Learn more at www.solvay.com. 19 Oct, 2022, 09:08 ET BOSTON and EMERYVILLE, Calif., Oct. 19, 2022 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA ), the leading horizontal platform for cell programming, and Zymergen. (RTTNews) - Cell programming firm Ginkgo Bioworks Holdings, Inc. (DNA) and biotechnology company Zymergen, Inc. (ZY) announced Monday they have entered into a definitive agreement under which. You can generally identify forward-looking statements by the use of forward-looking terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "explore," "evaluate," "intend," "may," "might," "plan," "potential," "predict," "project," "seek," "should," or "will," or the negative thereof or other variations thereon or comparable terminology. Ginkgo Bioworks is picking up a synthetic biology competitor in what it says is its largest M&A deal yet. We expect to leverage our new presence in the Boston area to step up and accelerate our offerings in this field.. Ginkgo also bought Zymergen for $300 million. Shares of biotechnology firm Zymergen ( ZY) jumped 20% during the morning session. However, that price is a long way from its peak last year, when it was trading at more than $34 a share. "Today marks an important step in our long-term growth as we complete the Zymergen acquisition and welcome their world-class team to Ginkgo," said Jason Kelly, CEO and co-founder of Ginkgo Bioworks. press@ginkgobioworks.com, ZYMERGEN INVESTOR CONTACT: Published: Oct 19, 2022 BOSTON and EMERYVILLE, Calif., Oct. 19, 2022 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, and Zymergen (Nasdaq: ZY) announced that Ginkgo has completed its previously announced acquisition of Zymergen. One, it means we have new investors in the company who make money with our success. Si vous ne souhaitez pas que nos partenaires et nousmmes utilisions des cookies et vos donnes personnelles pour ces motifs supplmentaires, cliquez sur Refuser tout. Filed by Ginkgo Bioworks Holdings, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do occur, what impact they will have on the results of operations, financial condition or cash flows of Zymergen or Ginkgo. Taking advantage of its location in a biotech talent pool and proximity to facilities and customers in the US, Solvay intends to turn this lab into a cornerstone of its growth strategy in renewable materials and biotechnology. Neither Zymergen nor Ginkgo assumes any duty to update or revise forward-looking statements, whether as a result of new information, future events or otherwise, as of any future date. Learn more at, Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. And then number two, obviously, it helps us preserve our cash margin of safety, like we said, right, we are protective of cash. Important risk factors could cause actual future results and other future events to differ materially from those currently estimated by management, including, but not limited to, the risks that: Ginkgo is unable to achieve the synergies and value creation contemplated by the acquisition; Ginkgo is unable to promptly and effectively integrate Zymergen's businesses, including retention of key personnel; Ginkgo management's time and attention is diverted on transaction related issues; disruption from the transaction makes it more difficult to maintain business, contractual and operational relationships; or adverse developments or outcomes of legal proceedings that are pending or instituted against Zymergen, Ginkgo or the combined company. We prefer it for two reasons. In gene therapy, Bluebird Bio expects to file in the first quarter for FDA approval of its third gene therapy candidate, lovotibeglogene autotemcel (lovo-cel) for sickle-cell disease, after gaining approvals for the other two in 2022. You are cautioned not to rely on Ginkgo's and Zymergen's forward-looking statements. He added, The access to capital that all these companies enjoyed back in 2019, 2020, and the early part of 2021I dont think well see that in the near term.. As of the end of Q1, Zymergen had approximately $336 million in cash on hand. Neither Zymergen nor Ginkgo assumes any duty to update or revise forward-looking statements, whether as a result of new information, future events or otherwise, as of any future date. Join our team of engineers, biologists, designers, dreamers, and more. He added, Those three categories will see us do a lot more deals., Ginkgo completed plenty of deals in 2022, including a partnership with Merck & Co. to engineer up to four enzymes toward active pharmaceutical ingredient manufacturing (up to $144 million in milestones). mesurer votre utilisation de nos sites et applications. "Today marks an important step in our long-term growth as we complete the Zymergen acquisition and welcome their world-class team to Ginkgo," said Jason Kelly, CEO and co-founder of Ginkgo Bioworks. These forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond Ginkgo's and Zymergen's control. Although primary data for the personalized cancer vaccine was expected in Q4 2022, the trials primary completion date is expected to be in September 2024. Powered by Madgex Job Board Software, https://www.prnewswire.com/news-releases/ginkgo-bioworks-completes-acquisition-of-zymergen-301653624.html. It then cut founding CEO Josh Hoffman the following August after customers complained that the companys product, Hyaline, did not work as advertised. Find the full press release here along with all of the latest news from the Ginkgo team. These factors include, among other things, general economic and business conditions; changes in global, political, economic, business, competitive, market and regulatory forces; judicial decisions; changes in tax laws, regulations, rates and policies; future business acquisitions or disposals; litigation and the ability of the combined company to protect its intellectual property rights; and the timing and occurrence (or non-occurrence) of other events or circumstances that may be beyond Ginkgos and Zymergens control. Under the terms of the merger agreement entered into on July 24, 2022, Zymergen stockholders received, for each share of Zymergen common stock, 0.9179 shares of Ginkgo Class A common stock. In addition, Zymergen will progress its cost restructuring measures, including headcount reductions and programme optimisation. The global synthetic biology marketsize was valued at USD 11 billion in 2021 and is poised to grow from USD 13.09 billion in 2022 to USD 55.37 billion by 2030, growing at a CAGR of 18. . GINKGO BIOWORKS INVESTOR CONTACT: Apr 04, 2023, 07:00 ET The investment will accelerate the development of new sustainable biopolymers, strengthening Solvay's position in biotechnology in this important growth platform. Founded in 1863, Solvay today ranks among the worlds top three companies for the vast majority of its activities and delivered net sales of 13.4 billion in 2022. Zymergen partners with nature to make better products, a better way, for a better world. Today, were pleased to announce our completed acquisition of Zymergen. Cell Therapy Services, Sustainable Innovation in Generic API Space with Centrient, Enabling development of sustainable chemicals and materials. Vous pouvez modifier vos choix tout moment en cliquant sur les liens Paramtres de confidentialit et des cookies ou Tableau de bord sur la confidentialit prsents sur nos sites et dans nos applications. Industry predictions for 2023 based on a survey of 150-plus biopharma leaders were recently offered by PPD, Thermo Fisher Scientifics clinical research business. All Rights Reserved. This observation was shared with GEN by Subin Baral, partner and global life sciences deals leader of Ernst & Young. You are cautioned not to rely on Ginkgo's and Zymergen's forward-looking statements. You can generally identify forward-looking statements by the use of forward-looking terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "explore," "evaluate," "intend," "may," "might," "plan," "potential," "predict," "project," "seek," "should," or "will," or the negative thereof or other variations thereon or comparable terminology. This growth platform complements the companys activities in three other key areas: battery materials, green hydrogen and thermoplastic composites. Kelly's stake will be worth well more than $700 million. Our events and newsletter mailings are a great way to learn about what's going on and keep up with the latest from our startups. Virtual Event: May 31 Let's go. New Kinpo Group (Daye Office) No.10, Daye Rd., Beitou District, Taipei City 112, Taiwan (R.O.C) Phone: +886-2-7705-8001 The company's platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Cision Distribution 888-776-0942 This acquisition will expand Solvays research and innovation (R&I) footprint in the US, provide Solvay access to new talents, and establish a sustainable growth base in synthetic biology in one the most important biotech hubs in the world, accelerating the companys biotech development plan. Synthetic biology, or synbio, has disrupted industries as diverse as agriculture, food, and fashion, in addition to the biopharma industry. Ginkgo BioWorks has signed a definitive agreement for the acquisition of biotechnology company Zymergen in an all-stock deal worth nearly $300m. Ginkgos biosecurity and public health unit, Concentric by Ginkgo, is building global infrastructure for biosecurity to empower governments, communities, and public health leaders to prevent, detect and respond to a wide variety of biological threats. Zymergen shares will no longer be traded on Nasdaq. These forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond Ginkgo's and Zymergen's control. GINKGO BIOWORKS INVESTOR CONTACT:investors@ginkgobioworks.com, GINKGO BIOWORKS MEDIA CONTACT:press@ginkgobioworks.com, ZYMERGEN INVESTOR CONTACT:investors@zymergen.com, View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-completes-acquisition-of-zymergen-301653624.html, https://www.prnewswire.com/news-releases/ginkgo-bioworks-completes-acquisition-of-zymergen-301653624.html, Norfolk Southern says East Palestine residents' suit barred by US law, Spotify lays off 200 employees from podcast division, Anna Shay, fan favorite on 'Bling Empire,' dead at 62, ChargePoint's stock swung wildly after releasing earnings, the company's CEO gives his take, Apple WWDC 2023: Here's everything announced at the tech giant's big event. When typing in this field, a list of search results will appear and be automatically updated as you type. In 2023, and possibly beyond 2023, lawsuits will play out between Pfizer/BioNTech and Moderna to settle disputes over mRNA vaccine patents. I cover breaking news with a focus on markets and sports business. Find the full press release here along with all of the latest news from the Ginkgo team. GINKGO BIOWORKS INVESTOR CONTACT:[emailprotected], GINKGO BIOWORKS MEDIA CONTACT:[emailprotected], ZYMERGEN INVESTOR CONTACT:[emailprotected]. Japanese bank SoftBank was the most notable investor in Zymergen, leading a $400 million funding round in 2018. The Group seeks to create sustainable shared value for all, notably through its Solvay One Planet roadmap crafted around three pillars: protecting the climate, preserving resources and fostering a better life. Through this multi-year strategic collaboration agreement, Solvay will join forces with Ginkgo to unlock the power of synthetic biology as an enabler of more sustainable chemicals and materials, contributing to the transition towards more environmentally-friendly solutions. The all-stock deal values Zymergen at $300 million market capitalization, a far cry from its roughly $3 billion valuation at its initial public offering last April. The price controls that the IRA imposes on medicines offered through Medicare may have the unintended consequence of reducing the number of new therapeutics created to respond to unmet medical needs, warned Jim Greenwood, Alex Pinson, and Jamie Gregorian of DLA Piper. Si vous souhaitez personnaliser vos choix, cliquez sur Grer les paramtres de confidentialit. For more information, visit, , or follow us on social media channels such as Twitter (@, Renewable Materials and Biotechnology growth platform, Cytec and Dralon Announce Strategic Collaboration, Mubadala and Cytec Announce Strategic Collaboration, Solvay expands R&I center to internationalize its oil & gas business, Solvay inaugurates state-of-the-art innovation pilot unit for solid state batteries in Europe, Solvay adds new thermoplastic composite capacity in the United States, Solvay announces the production of a new generation solvent at its Melle site. Now the company has been picked up by Ginkgo Bioworks, which . See All Our Local Websites | Our Worldwide Presence, ICP15007541-5 | 31011202001085, About Solvays Renewable Materials and Biotechnology platform, Solvay, a leading science and materials company whose technologies bring benefits to many aspects of daily life, today announced a strategic collaboration with, This partnership is designed to strengthen Solvays position in biotechnology as part of the, Were thrilled to make this important investment and to partner with Ginkgo Bioworks on an exciting project to develop sustainable chemicals and materials, allowing us to provide innovative biotechnologies to new markets, said, Were so excited to welcome Solvay to our platform and to the Boston area at such a pivotal growth period for both of our companies. Sign up for the QB3 newsletter. Ginkgo has also actively supported a number of COVID-19 response efforts, including K-12 pooled testing, vaccine manufacturing optimization and therapeutics discovery. Additional information concerning these risks, uncertainties and assumptions can be found in Ginkgo's and Zymergen's respective filings with the SEC, including the risk factors discussed in Ginkgo's most recent Annual Report on Form 10-K, as updated by its Quarterly Reports on Form 10-Q, in Zymergen's most recent Annual Report on Form 10-K, as updated by its Quarterly Reports on Form 10-Q, and in Ginkgo's future filings with the SEC. Have you registered yet? Ginkgo Bioworks ( NYSE: DNA) has entered into an agreement to acquire Zymergen ( ZY ). DNA 6.85% SOLB +3.85%. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Ferment 2023 is April 19! Theres a lot of collaboration and partnerships that we see, Baral noted, and well continue to get early innovation on cell and gene therapies.. Very proud and thankful to all current and former colleagues! "Zymergen's . Jul. These forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond Ginkgo's and Zymergen's control. Also declining were biotech special purpose acquisition company (SPAC) IPOs, with 10 biotech firms, and another 6 that revealed SPAC plans in 2021, completing mergers with blank-check companies. Where patient affordability improves, manufacturers may also realize some volume offsets, observed Muna Tuna, U.S. market access, pricing, and reimbursement leader, Ernst & Young. These trends are detailed in this article. Statements in this press release that are forward-looking, including the expected benefits of Ginkgo's acquisition of Zymergen, are based on management's current estimates, assumptions and projections, and are subject to significant uncertainties and other factors, many of which are beyond Ginkgo's and Zymergen's control. This is our largest acquisition to date! The leading site for news and procurement in the pharmaceutical industry, Transforming MedTech and Pharma using Software as a Medical Device (SaMD), Accelerating Biopharmaceutical Innovation, Precision medicine and digital health innovation for disease diagnosis, care and treatment, Enabling process intensification in biopharma manufacturing, Specialty drug launch strategy and operations, The next chapter of clinical trial services, Putting quality first in the pharma supply chain, Enabling better biopharmaceutical manufacturing, Pharmaceutical Grade Silicone Manufacturer, Cybersecurity in pharma: Securing the future, ASCO 2023: Keytruda becomes a new option in perioperative NSCLC, Revised EU/Pfizer/BioNTech Covid-19 vaccine deal may lead to a Comirnaty monopoly, PharmaEssentia picks Pint-Pharma to market BESREMi in Latin America, Chinas NMPA accepts Akesos NDA for ebronucimab, Innovation in immuno-oncology: Leading companies in T-cell culturing, XtalPi announces $250m AI drug discovery collaboration with Eli Lilly, University of Sydney will use AI to boost cancer drug research, Whos investing where? Optimizing Crucial Drug Manufacturing of APIs with Merck, Introducing: Bioworks7 Mammalian Screening at Scale, Acquiring Altar and Circularis to Strengthen Our Capabilities. It has lesser interest in the. As for future M&A deals, Kelly said that we wouldnt probably see anything else major through the rest of this year as the company prepares to merge with Zymergen. So thats a good thing. Private equity deal activity in the pharmaceutical industry in Europe decreased by 29% in Q1 2023, Whos acquiring who? All rights reserved. "Today marks an important step in our long-term growth as we complete the Zymergen acquisition and welcome their world-class team to Ginkgo," said Jason Kelly, CEO and co-founder of Ginkgo Bioworks. Ginkgo has also actively supported a number of COVID-19 response efforts, including K-12 pooled testing, vaccine manufacturing optimization and therapeutics discovery. For more information, visit www.ginkgobioworks.com. afficher des publicits et des contenus personnaliss en fonction de vos profils de centres dintrt; mesurer lefficacit des publicits et contenus personnaliss; et. You are cautioned not to rely on Ginkgos and Zymergens forward-looking statements. Under the terms of the merger agreement entered into on July 24, 2022, Zymergen stockholders received, for each share of Zymergen common stock, 0.9179 shares of Ginkgo Class A common stock. Some biotech investors believe this valuation is excessive for a company with little revenue; in 2020 Ginkgo brought in $77 million . Headquartered in Boston, Ginkgo Bioworks uses the most advanced technology on the planetbiologyto grow better products. Statements in this press release that are forward-looking, including the expected benefits of Ginkgo's acquisition of Zymergen, are based on management's current estimates, assumptions and projections, and are subject to significant uncertainties and other factors, many of which are beyond Ginkgo's and Zymergen's control. Ferment 2023 is April 19! Ginkgo Bioworks acquired biotechnology firm Zymergen, the synthetic biology companies announced Monday morning, marking the final act in Zymergens dramatic and brisk fall from grace. Biotech is the future and this step is an important milestone for our growth platform. Login or create a forever free account to read this news. Jason Kelly Announcements Tracking Pathogen Variants with Rwanda Biomedical Centre February 15, 2023 Announcements New Biosecurity Capabilities in the Democratic Republic of the Congo April 14, 2023 Growing Ginkgo's Platform with Digital Technology Read More The latter factor is what Ernst & Young calls firepower., The good deals are getting done, Baral pointed out. Cell Therapy Services, Sustainable Innovation in Generic API Space with Centrient. Ginkgos biosecurity and public health unit, Concentric by Ginkgo, is building global infrastructure for biosecurity to empower governments, communities, and public health leaders to prevent, detect and respond to a wide variety of biological threats. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do occur, what impact they will have on the results of operations, financial condition or cash flows of Zymergen or Ginkgo. Following a $400 million Series C back in 2018 and a $300 million raise in 2020, Zymergen went public last April with an eye-popping IPO worth $500 million. Some of these predictions are among the seven biopharma-related trends that GEN has uncovered in its interviews with experts and other industry stakeholders, and in its reviews of reports and public statements. So far, 40% of Zymergen investors have pre-approved the deal, Ginkgo CEO Jason Kellytells Endpoints News. In our case, it's fantastic to be able to integrate platform capabilities from Zymergen and make them accessible to our partners so quickly, said, Jason Kelly, CEO and co-founder of Ginkgo Bioworks, Solvay is a science company whose technologies bring benefits to many aspects of daily life. This study compared changes in plasma complement component 1q (C1q), apelin and adropin concentrations in older obese women after descending (DSW) and ascending stair walking (ASW) training (n = 15/group) performed twice a week for 12 weeks, with gradual increases in exercise time from 5 to 60 min. Ginkgo also bought Zymergen for $300 million. The Group seeks to create sustainable shared value for all, notably through its Solvay One Planet roadmap crafted around three pillars: protecting the climate, preserving resources and fostering a better life. As part of this partnership, Solvay will also acquire a Ginkgo (formerly Zymergen) laboratory in Cambridge, Massachusetts. In our case, it's fantastic to be able to integrate platform capabilities from Zymergen and make them accessible to our partners so quickly, said Jason Kelly, CEO and co-founder of Ginkgo Bioworks, Synthetic biology can help companies across a wide breadth of markets reach their environmental and economic goals at the same time, and its thrilling to work with a partner taking such a big swing at sustainability.. The slowdown in private and public financings is one factor expected to drive merger and acquisition (M&A) deals in 2023, Baral remarked. Ginkgo put out word early Monday it is acquiring Zymergen in an all-stock deal, valuing the Emeryville, CA-based synthetic biology biotech at around $300 million. As part of this partnership, Solvay will also acquire a Ginkgo (formerly Zymergen) laboratory in Cambridge, Massachusetts. The company's platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Growing regulatory acceptance of cell and gene therapies26 have been approved by the FDA, 4 in 2022 alonewill spur additional development efforts. from 8 AM - 9 PM ET. Ginkgo's acquisition of Zymergen: 'Like Lego pieces you could take in and out'. Putting our platform capabilities to work on sustainability, Were thrilled to make this important investment and to partner with Ginkgo Bioworks on an exciting project to develop sustainable chemicals and materials, allowing us to provide innovative biotechnologies to new markets, said Solvay CEO Ilham Kadri. According to the agreement, 5.25% of the pro forma merged business will be owned by the stockholders of Zymergen following the acquisition. In September, Merck & Co. exercised its option to jointly develop and commercialize Modernas messenger RNA (mRNA)-based personalized cancer vaccine, for which Merck agreed to pay Moderna $250 million upfront. But to prove their mettleand repay investorsthe start-ups need their new and better microbes to be put to work churning out products that people will buy. To learn more about Ginkgo Enzyme Services, please visit ginkgobioworks.com/enzyme-services/. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For more information, visit ginkgobioworks.com and concentricbyginkgo.com, read our blog, or follow us on social media channels such as Twitter (@Ginkgo and @ConcentricByGBW), Instagram (@GinkgoBioworks and @ConcentricByGinkgo), or LinkedIn. Ginkgo Class A common stock will continue to trade on NYSE under the ticker symbol DNA. The deal to combine two complementary companies with identical visions is anticipated to expedite the development of the innovative horizontal synthetic biology platform of Ginkgo. Solvay, a leading science and materials company whose technologies bring benefits to many aspects of daily life, today announced a strategic collaboration with Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity. , . Solvay, a leading science and materials company whose technologies bring benefits to many aspects of daily life, today announced a strategic collaboration with Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity. Last spring, GEN reported on companies applying emerging technologies that included Cas13-encoding mRNA, circular mRNA, programmable mRNA, and self-amplifying mRNA. The deal has been approved by both companies board of directors, and is slated to close sometime in the first quarter next year. Furthermore, the extension of the biological assets (Codebase) library of Ginkgo following the takeover of Zymergen will be beneficial to the customers of the former. Discussions for this deal, according to Ginkgo, started just two months ago after Ginkgo submitted the first bid to acquire Zymergen in May. Love in every #TradingView. This is our largest acquisition to date! Recent Press Read More Filter Posts: All Ginkgo in the News Press Releases Download Our Press Kit May 25, 2023 Ginkgo Bioworks and Centrient Pharmaceuticals Announce Expansion of Partnership Following Success of Initial Project to Bring Sustainable Innovation to the Generic API Space Ginkgo Press May 10, 2023 The drug pricing debate is unlikely to be resolved by a Congress divided between the House of Representatives narrow Republican majority and the Senates slim Democratic majority, shaken when Arizona Senator Kyrsten Sinema announced that she had left the Democratic Party and registered as an independent. Zymergen is a biotech company that designs and produces molecules, microbes and materials for diverse end markets. Through the takeover, the company will support plans of Zymergen to assess strategic options for their Advanced Materials and Drug Discovery businesses. The California-based venture quickly unraveled, and the stock fell 68% on August 3, after the company reported its bleak revenue outlook.
Cantu Shea Butter Maximum Hold Styling Gel, Animal Hooded Towel Baby, How Much Does Hair Dusting Cost, Arrma Metal Diff Case Ara311061, Vacuum Sealed Brisket Sell By Date, Scorpion Exo-com Manual,
certificate course in epidemiology